The company intends to use the funds to advance the development of its RNA therapies and expand its deep phenotyping platform to identify and validate new liver targets. The round was led by Khosla Ventures, with participation from Backed VC, Apollo Health Ventures, Selvedge, Hoxton, and Hermes-Epitek.
In addition to deep phenotyping of human livers, the company is able to test therapeutics in explanted livers being maintained extracorporeally. They have developed a full-stack GalNAc-siRNA development process, through validating candidates in these actively perfused human livers.
Led by Quin Wills, M.D., Ph.D., Chief Scientific Officer, and Co-Founder, and Jack O’Meara, CEO & Co-Founder, Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases. The company has built a deep phenotyping platform to identify novel liver targets, validated directly in discarded human livers kept alive on machines. Using deep phenotyping (‘phenomics’), Ochre Bio digitizes liver biology at scale. It has already generated massive amounts of spatial genomics data from freshly donated human livers, and have uncovered hundreds of novel potential liver targets that are currently being validated in their labs.
News Highlights Business
- Ochre Bio raises $ 9.6 million in seed funding
- Check all news and articles from the Business news updates.